RE: Gallop Oncology's LYT-200 in AML7 Dec 2025 13:22
Some clarification on autologous, allogeneic, ex vivo and in vivo CAR-T cell therapies. These terms describe two fundamental aspects of CAR-T cell therapies: the source of the T cells used for treatment and the location where the genetic modification occurs.
• Autologous (Self-Derived): Autologous therapies use a patient's own T cells as the starting material. This personalized approach ensures the modified cells are a perfect match for the patient's immune system, which eliminates the risk of immune rejection or graft-versus-host disease (GvHD). The main drawbacks are the high cost, complex logistics, and a prolonged manufacturing time of several weeks (the "vein-to-vein" time).
• Allogeneic (Donor-Derived): Allogeneic therapies use T cells harvested from healthy donors to create "off-the-shelf" products that can be mass-produced, stored, and administered immediately when a patient needs treatment. This approach addresses the accessibility and timing issues of autologous therapy, which is crucial for patients with rapidly progressing cancers. However, it requires additional genetic engineering (e.g., using CRISPR) or immunosuppressive drugs to prevent the recipient's immune system from rejecting the donor cells or the donor cells from attacking the patient's body (GvHD).
• Ex Vivo (Outside the Body): This approach involves removing a patient's or donor's T cells from the body (via a procedure like leukapheresis) and sending them to a specialized laboratory. In the lab, the cells are genetically engineered with the Chimeric Antigen Receptor (CAR) construct, multiplied to therapeutic quantities, and then infused back into the patient. This is the manufacturing method used for nearly all currently approved commercial CAR-T cell therapies.
• In Vivo (Inside the Body): This is an emerging, experimental strategy designed to simplify the manufacturing process and reduce costs. Instead of removing cells, the genetic material needed to create the CAR (typically packaged in a viral vector or lipid nanoparticle) is injected directly into the patient's bloodstream. The goal is to program the T cells to express the CAR in situ (within the body itself).
In essence, ex vivo vs. in vivo is about where the engineering happens (outside or inside you), while allogeneic vs. autologous is about whose cells are used (donor vs. patient). HG-CT-1 is an autologous ex vivo treatment.
- - - - -
Allogene is one company pursuing allogeneic CAR-T cell therapy: https://allogene.com/science/
Their ALLO-819 for AML was dropped some time in the last year: https://web.archive.org/web/20241108075452/https://allogene.com/web/20241108075452/https://allogene.com/pipeline/ vs. https://allogene.com/pipeline/
Sign In
Follow the stocks
